AIxCrypto Holdings, Inc. Annual Report: A Breakdown for Investors

I’ve put together this guide to help you understand how AIxCrypto Holdings, Inc. (formerly Qualigen Therapeutics) performed this year. The company has undergone a total transformation, and it is important to look past the buzzwords to see what is actually happening with your investment.

---

1. What does this company do?

AIxCrypto (AIXC) has rebranded from a drug developer to a tech firm. They are currently focused on two primary revenue streams:

• Real-World Asset (RWA) Tokenization: They are building a platform to fractionalize and trade traditional assets, aiming to capture a 0.5% transaction fee.
• Embodied AI (EAI): They are developing a decentralized computer network for autonomous agents. This software is designed to facilitate machine-to-machine payments and data verification, with "Agent-Pay" tools scheduled for a third-quarter 2026 launch.

2. Major Changes: The "Pivot"

The company is moving quickly to execute a "Dual Flywheel" strategy. They intend to use their RWA platform to gather data, which will then train their AI models to automate the tokenization process.

In February 2026, the company shut down its "BesTrade" and "C10" product lines, resulting in a $4.2 million loss related to closing that infrastructure. Additionally, the legacy drug-development business—including the QN-302 cancer program—is currently for sale. These legacy programs continue to cost the company $650,000 per month to maintain.

3. Financial Health: The "Going Concern" Warning

The company’s auditors have issued a "going concern" warning, signaling that there is significant doubt regarding the company's ability to continue operations.

• Cash Position: The company reported a $28.5 million loss this year. With only $9.2 million in cash remaining and a monthly burn rate of approximately $1.8 million, the company has less than six months of runway.
• Operational Costs: The company operates with a small team of 10 employees and pays Faraday Future $125,000 per month for administrative and legal support.
• Shareholder Dilution: Because the company has no revenue from its new segments, it relies on selling additional stock to fund operations. Over the last year, the issuance of new shares has reduced existing shareholder ownership by 45%.

4. Key Risks

• Capital Requirements: The company requires an estimated $20 million in additional funding to survive through 2026. Without this capital, the company faces a high risk of insolvency.
• Unproven Business Model: The "Dual Flywheel" strategy is currently in the research phase. As of the latest report, the company has generated $0 in revenue from these new segments.
• Operational Dependencies: The agreement with Faraday Future can be canceled with 30 days' notice. This partnership currently provides both operational support and the data necessary for AI testing.
• Market Sensitivity: The company’s valuation is tied to the volatile crypto and AI sectors, which often experience significant downward pressure during broader market corrections.

---

Final Thoughts for Investors

AIxCrypto is currently operating as a startup with a new identity and a very thin financial cushion. The company is burning through its remaining cash to develop products that have yet to generate revenue. When evaluating this investment, consider that the company’s survival is entirely dependent on its ability to secure further funding and successfully transition its unproven technology into a profitable business model.